Asia Healthcare Tour Takeaways We recently visited Hengrui during our Grand Asia Healthcare Tour during Sep 17-26. Below are key takeaways with full transcripts attached. Deep Pipeline Across Core Therapeutic Areas with Differentiated Modalities China (PRC) | Pharmaceuticals Global Value Maximization Through Flexible Partnering Models Hengrui's ex-China strategy focuses on unlocking full asset value through a combination of out-licensing and equity-linked NewCo structures. Recent transactions, such as the G ...

Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical - known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) - and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public offering (IPO ...

Summary of China Pharma and Biotech Sector Conference Call Industry Overview - The Chinese pharmaceutical and biotech sector is experiencing a significant rally, with the Hang Seng Biotech and MSCI China Healthcare indices showing year-to-date (YTD) returns of 57% and 38%, respectively, outperforming broader market indices which are at 16-20% [1][10][26] - Public financing has increased fourfold in the first half of 2025 compared to the same period in 2024, driving IPO activity on the Hong Kong Stock Exchange, particularly in biotech [1][40] - Despite the rally, valuations have sharply re-rated, with China's biotech price-to-sales multiples now aligning with global peers, suggesting limited further upside compared to the peaks of 2020-2021 [1][11] Key Growth Drivers - Oncology and metabolic diseases are identified as primary growth drivers, with significant market potential in PD-1-based bispecific antibodies and GLP-1 drug classes [3][4] - The global market for PD-1-based bispecific antibodies could reach US$70-80 billion, while the domestic GLP-1 market is projected to hit CNY87 billion by 2035 [3] - Chinese companies are competitive in clinical results, particularly in lung cancer treatments, and domestic GLP-1 drugs are matching international efficacy [3][4] Company Highlights - **Akeso**: Leading in PD-1/VEGF bispecific antibodies with multiple phase 3 trials; however, overall survival results remain uncertain [4] - **Innovent**: Offers a diversified portfolio across various disease areas and leads in advanced antibody modalities [4] - **Hansoh**: Transitioning to innovation-driven growth with strong sales in its 3rd-generation EGFR inhibitor and significant GLP-1 business development deals [4] R&D and Innovation - The sector is shifting from me-too drugs to best-in-class and first-in-class assets, focusing on novel targets and drug combinations [2][38] - Clinical trial activity is robust, with Chinese assets comprising over 50% of new global trials in 2025 [2][42] - The number of new clinical trials has shown stable growth, with a notable increase in innovative drug approvals [42][65] Policy Environment - Government policies have fluctuated but are currently favorable, balancing innovation stimulation with price control [2][43] - Recent supportive policies include initiatives to cover innovative drugs under commercial insurance, indicating a long-term positive outlook for the sector [43] Out-Licensing Trends - Out-licensing activity has surged in 2025, with total deal value reaching US$59 billion, surpassing the previous year's total [72] - The focus has shifted from PD-1 drugs to PD-1/VEGF and GLP-1 assets, with significant deal values and upfront payments [75][72] - Despite the increase in total deal value, upfront payments in China still lag behind developed markets, indicating a need for caution regarding the sustainability of this growth [73][81] Investment Implications - Companies such as Akeso, Hansoh, Innovent, and Hengrui are rated as Outperform, while BeiGene, CSPC, Sino Biopharm, and Zai Lab are rated as Market-Perform [7] - The current rally may require new catalysts beyond existing out-licensing deals to sustain momentum, as valuation headroom appears limited [5][22] Conclusion - The Chinese pharma and biotech sector is evolving into a mature, innovation-driven industry with growing global competitiveness, tempered by valuation caution and sector uncertainties [5][11]

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **biopharmaceutical sector in China**, highlighting its resurgence driven by innovation and increased deal activity with multinational corporations (MNCs) [1][2]. Core Insights - **Global Competitiveness**: China's pharma sector is confirmed to be globally competitive, with significant partnerships such as Summit Therapeutics' licensing agreement with Akeso for ivonescimab (up to $5 billion) and Pfizer's deal with 3SBio for SSGJ-707 (up to $6 billion) [2]. - **Investment in Obesity Treatments**: Companies are investing in the obesity treatment space, with notable deals including Merck's $1.9 billion agreement with Hansoh Pharma and Novo's $2 billion deal with United Bio-Technology [2]. - **Long-Term Winners**: AstraZeneca (AZN) and Sanofi (SAN) are identified as long-term winners in the region, with both companies actively investing and expanding their R&D presence in China [7][11]. R&D and Business Development Opportunities - **Rapid R&D Advancement**: China's biopharma industry is shifting from generics to genuine innovation, with improved R&D efficiency and lower costs [8][41]. - **Rich Pipeline of Assets**: MNCs are increasingly seeking business development (BD) deals in China, with a wealth of attractive pipeline assets available for international partnerships [9]. - **Key Asset Types**: Bispecific antibodies, GLP-1 therapies, and antibody-drug conjugates (ADCs) are highlighted as prominent areas for BD opportunities [10][65]. Market Dynamics - **Market Share Growth**: The share of innovative drugs in China's core hospital pharmaceutical market increased from 21% in 2015 to 29% in 2024, with local companies' share rising from 18.7% to 27.8% [24][25]. - **Declining Contribution**: There is a modest decline in China sales as a percentage of global sales among large-cap EU pharma companies, with AstraZeneca's share dropping from 20% in 2020 to an estimated 12% in 2024 [29][31]. Strategic Collaborations - **M&A Activity**: The report notes a boom in M&A activity as companies seek to acquire innovative pipeline assets amid global pricing pressures and patent expirations [40]. - **Emerging Global Innovation Hub**: China is becoming a global hub for innovative drug R&D, with a significant increase in out-licensing deals, reaching a total value of $50.8 billion in 2024 [40][48]. Specific Therapeutic Areas - **Bispecific Antibodies**: The report emphasizes the growing interest in bispecific antibodies, particularly those targeting PD-1/VEGF pathways, with significant licensing deals indicating global confidence in these assets [66][68]. - **GLP-1 Therapies**: The report outlines the evolution of GLP-1 therapies, with a focus on long-acting formulations and oral small molecules, highlighting numerous ongoing clinical trials and licensing deals [70][72]. - **Antibody-Drug Conjugates (ADCs)**: China is emerging as a leader in ADC innovation, with approximately 40% of the global ADC pipeline originating from China and a significant increase in international licensing transactions [77][78]. Conclusion - The biopharmaceutical sector in China is positioned for growth, with strong R&D capabilities, a rich pipeline of innovative assets, and increasing global interest from MNCs. Companies like AstraZeneca and Sanofi are well-positioned to capitalize on these opportunities, while the landscape for innovative therapies continues to evolve rapidly.

Financial Data and Key Metrics Changes - Corteva reported a 15% year-over-year increase in Q1 EBITDA, with nearly 400 basis points of margin expansion driven by strong cost execution [7][20] - Organic sales were up 3% compared to last year, with seed sales increasing by 2% and crop protection sales by 3% [20][22] - Operating EBITDA margin reached nearly 27%, up 390 basis points, supported by organic sales growth and lower input costs [23] Business Line Data and Key Metrics Changes - The seed business saw organic sales increase by 2%, driven by pricing, while crop protection organic sales rose by 3%, supported by double-digit volume growth for new products and biologicals [11][12] - Seed volume decreased by 1% year-over-year, while crop protection volume increased by 5%, with notable double-digit volume gains from new products [21][22] Market Data and Key Metrics Changes - In the U.S., farmers are projected to shift planted area from soybeans to corn, resulting in a projected 5% increase in corn planting [9] - Enlist beans are expected to be planted on over 65% of U.S. soybean acres in 2025, indicating strong market demand [9] - The crop protection market is anticipated to remain flat with low single-digit volume gains, while Corteva expects high single-digit volume gains to offset low single-digit pricing headwinds [12][28] Company Strategy and Development Direction - Corteva aims to become the leading provider of soybean technology in Brazil, having sold over 3 million units of Conquesta E3 soybeans in the last three years [9] - The company is transitioning to a net out-licenser of technology, with expectations of generating $65 million in benefits this year [19] - The focus on operational excellence and cost improvements is expected to generate net cost savings of $400 million [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the first quarter performance, noting double-digit EBITDA gains and margin improvements despite potential risks in the second half of the year [18] - The tariff situation is viewed as manageable, with a direct cost impact of approximately $50 million anticipated for 2025 [15][16] - Management highlighted the importance of American farmers and the need for export markets to open up for North American grain and oilseeds [17] Other Important Information - The company plans to introduce approximately 500 new products to the market this year, including around 300 new seed hybrids and varieties [11] - Currency fluctuations posed a significant headwind, impacting sales by approximately 5% [20][24] - Corteva is on track for $1 billion in share repurchases in 2025 [34] Q&A Session Summary Question: Risks in the second half of the year - Management acknowledged the risks but noted that the second half has been derisked since the February guidance, with expectations for crop protection in Brazil to match last year's strong performance [41][42] Question: Price environment in crop protection - Management indicated that while pricing pressures are expected to continue, there are signs of stabilization in the market, particularly with generics from China [66][70] Question: Updates on new growth platforms - Management confirmed that the launch of hybrid red winter wheat is still on track for 2027, with significant revenue potential, and the pilot program for winter canola is expanding [80][81] Question: Tariff impact clarification - Management clarified that the $50 million tariff impact is manageable and not included in the current guidance, as they are working on mitigation strategies [85] Question: Positioning for soybean market shifts - Management noted that U.S. soybean production is essential to meet global demand, despite shifts in imports to Brazil, and emphasized the importance of reopening export markets [92][93]